Skip to content
PubMed This is a summary of 10 peer-reviewed journal articles Updated
Oncology

Treatment and Care: Choosing Your Path

At a Glance

MALT lymphoma is a highly treatable, slow-growing cancer. For gastric MALT driven by H. pylori, treatment usually starts with antibiotics. For non-gastric or advanced cases, doctors may recommend targeted radiation, immunotherapy like rituximab, or a watch-and-wait approach to avoid overtreatment.

The most empowering thing to know about MALT lymphoma is that it is highly treatable. Because it is an indolent (slow-growing) cancer, doctors often have the luxury of time to choose the least aggressive treatment that will be effective [1]. In many cases, the “treatment” isn’t even a traditional cancer drug—it’s a targeted course of antibiotics [2].

The Gastric MALT Strategy: Fighting the Cause

If your lymphoma is in the stomach (gastric), the first question is whether an infection is driving it.

If you are H. pylori Positive (+):

The standard first-line treatment is antibiotics to eradicate the H. pylori bacteria [3][4].

  • The Goal: By killing the bacteria, you remove the “fuel” for the lymphoma.
  • The Success Rate: A vast majority of localized patients achieve complete remission with antibiotics alone [3].
  • The Timeline: Remission isn’t instant. It can take several months—sometimes up to a year—for the lymphoma cells to fully disappear after the bacteria are gone [5].

If you are H. pylori Negative (-) or Antibiotics Fail:

If the bacteria aren’t there, or if the lymphoma persists after antibiotics (often because of the t(11;18) translocation), the next step is usually Involved-Site Radiation Therapy (ISRT) [6]. This is a highly targeted form of radiation that treats just the stomach.

  • Side Effects: ISRT is generally well-tolerated but can cause local fatigue, mild skin irritation, and temporary nausea. Long-term side effects are typically minimal [6].

The Non-Gastric MALT Strategy: Targeted Precision

For MALT lymphoma in other areas—like the eyes, salivary glands, or lungs—the strategy is slightly different because there isn’t always a clear bacterial “trigger” to treat with antibiotics.

  • Localized Disease (Stage I/II): Radiation therapy is the “gold standard” for localized non-gastric MALT (like ocular or salivary gland cases) [7][8]. It is highly effective and often curative. Again, side effects depend on the area treated but mostly involve local irritation and fatigue.
  • Watch and Wait: Because these tumors grow so slowly and may not cause symptoms for years, some doctors may suggest “watchful waiting”—monitoring the site with regular scans or bloodwork but holding off on treatment until it’s truly necessary. During this time, you will still have frequent check-ups to ensure the disease is not progressing.

Advanced or Disseminated Disease

If the lymphoma has spread to multiple sites (Stage III or IV), local treatments like radiation aren’t enough. In these cases, systemic (full-body) therapy is used [9].

  1. Rituximab (Rituxan): This is an immunotherapy. It is an antibody that specifically targets and kills B-cells [10]. Side Effects: It can cause immunosuppression (lowered ability to fight infections) and infusion reactions (fever or chills while receiving the drug).
  2. Chemotherapy Combinations: For more active disease, Rituximab may be paired with chemotherapy drugs like Chlorambucil [9]. Side Effects: Chemotherapy side effects vary depending on the drug but may include fatigue, lowered blood cell counts, and nausea. These combinations are very effective at putting the disease into long-term remission [9].

A Note on Overtreatment

Because MALT lymphoma is so slow-growing, it is important to avoid treatments that are more aggressive than necessary. Your care team will aim for the “minimum effective dose” to keep you healthy while preserving your quality of life.

Return to Home Page

Common questions in this guide

Can antibiotics really cure MALT lymphoma?
Yes, for many patients with gastric MALT lymphoma driven by an H. pylori infection, a targeted course of antibiotics to clear the bacteria can put the lymphoma into complete remission. It can take several months for the lymphoma cells to fully disappear after the bacteria are gone.
What if antibiotics don't work or I don't have an H. pylori infection?
If the bacteria are not present, or if the lymphoma remains after antibiotic treatment, the next standard step is usually Involved-Site Radiation Therapy (ISRT). This is a highly targeted form of radiation that treats just the stomach.
Why did my doctor suggest a watch-and-wait approach?
Because MALT lymphoma grows very slowly and may not cause symptoms for years, doctors may recommend regular monitoring with scans and bloodwork instead of immediate treatment. This allows you to avoid treatment side effects until therapy is truly necessary.
When are chemotherapy or immunotherapy used for MALT lymphoma?
If the lymphoma has spread to multiple sites, systemic therapies are often used. This can include immunotherapy drugs like rituximab, which specifically target and kill B-cells, sometimes paired with chemotherapy drugs to put the disease into long-term remission.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my H. pylori status, is antibiotic therapy the best first step, or do my other markers (like t(11;18)) suggest we should start with radiation?
  2. 2.If we start with antibiotics, how soon should we do the first follow-up breath test and endoscopy?
  3. 3.For my non-gastric MALT, is radiation therapy considered 'curative,' and what are the potential long-term side effects for that specific body part?
  4. 4.If my lymphoma is advanced (Stage III or IV), what is the benefit of adding rituximab to chemotherapy?
  5. 5.Since this is a slow-growing cancer, is a 'watch-and-wait' approach an option for me right now?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (10)
  1. 1

    MALT lymphoma affecting the oral cavity: a clinical, pathologic and genetic study of MALT1 gene translocation.

    Legarrea JMA, Santos MLD, Rodrigues NG, et al.

    Oral surgery, oral medicine, oral pathology and oral radiology 2025; (140(6)):740-747 doi:10.1016/j.oooo.2025.07.016.

    PMID: 40858407
  2. 2

    Diagnosis and Treatment for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma.

    Nakamura S, Hojo M

    Journal of clinical medicine 2022; (12(1)) doi:10.3390/jcm12010120.

    PMID: 36614921
  3. 3

    Helicobacter pylori and Gastric Cancer.

    Kim J, Wang TC

    Gastrointestinal endoscopy clinics of North America 2021; (31(3)):451-465 doi:10.1016/j.giec.2021.03.003.

    PMID: 34053633
  4. 4

    Anti-Helicobacter pylori therapy in localized gastric mucosa-associated lymphoid tissue lymphoma: A prospective, nationwide, multicenter study in Japan.

    Sugizaki K, Tari A, Kitadai Y, et al.

    Helicobacter 2018; (23(2)):e12474 doi:10.1111/hel.12474.

    PMID: 29504247
  5. 5

    Helicobacter pylori Reinfection Diagnosed by Endoscopic and Histologic Recurrence in a Patient with Gastric Mucosa-Associated Lymphoid Tissue Lymphoma.

    Sugiyama T, Nanjyo S, Nakajima T, Kato C

    Case reports in gastroenterology 2023; (17(1)):41-48 doi:10.1159/000528309.

    PMID: 36742100
  6. 6

    Gastric MALT-Lymphoma: more than Helicobacter Pylori.

    Van de Vyver G, Vandamme T, Steger PH, Staessen D

    Acta gastro-enterologica Belgica 2021; (84(4)):657-659 doi:10.51821/84.4.016.

    PMID: 34965047
  7. 7

    An Epidemiological Study on Survival in Lymphoma of Mucosa-Associated Lymphoid Tissue: A Comparative Analysis by Primary Tumor Location.

    Chen GP, Lu ZZ, Lu GZ, et al.

    Journal of investigative surgery : the official journal of the Academy of Surgical Research 2025; (38(1)):2523858 doi:10.1080/08941939.2025.2523858.

    PMID: 40586267
  8. 8

    Extranodal Marginal Zone B-cell Lymphoma of the Ocular Adnexa.

    Guffey Johnson J, Terpak LA, Margo CE, Setoodeh R

    Cancer control : journal of the Moffitt Cancer Center 2016; (23(2)):140-9 doi:10.1177/107327481602300208.

    PMID: 27218791
  9. 9

    Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.

    Zucca E, Conconi A, Martinelli G, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(17)):1905-1912 doi:10.1200/JCO.2016.70.6994.

    PMID: 28355112
  10. 10

    Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.

    Salar A, Domingo-Domenech E, Panizo C, et al.

    Blood 2017; (130(15)):1772-1774 doi:10.1182/blood-2017-07-795302.

    PMID: 28801448

This page explains MALT lymphoma treatment options for educational purposes only. Always consult your oncology team to determine the best treatment plan for your specific diagnosis.

Get notified when new evidence is published on MALT lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.